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Edited by Frances ShannonAbstract The potential use of a-cyclodextrin and its hydro-
philic a-cyclodextrin derivatives (a-CyDs) as antagonists against
lipopolysaccharide (LPS), which stimulates the nitric oxide
(NO) and tumor necrosis factor-a (TNF-a) production as well
as nuclear factor-jB (NF-jB) activation in macrophages was
examined. Of three a-CyDs used in the present study, 2,6-di-
O-methyl-a-CyD (DM-a-CyD) had greater inhibitory activity
than did the other CyDs against NO and TNF-a production
through an impairment of gene expression in macrophage cell
lines and primary macrophages stimulated with LPS and lipid
A in a concentration-dependent manner. Concomitantly, DM-
a-CyD inhibited NF-jB translocation into nucleus. These inhib-
itory eﬀects of DM-a-CyD could be attributed to the release of
CD14 from lipid rafts caused by an eﬄux of phospholipids, but
not cholesterol. These results suggest that DM-a-CyD may have
promise as a potent and unique antagonist for excess activation
of macrophages stimulated with LPS.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Lipopolysaccharide (LPS) is an integral component of the
outer membrane of gram-negative bacterial, consisting of a
hydrophilic polysaccharide and a highly conserved hydropho-
bic lipid A portion [1]. LPS is conserved microbial molecules
(pathogen-associated molecular patterns), which can stimulate
both innate and adaptive immune responses, particularly on
macrophages and dendritic cells. Actually, serum LPS is car-
ried in the body by a speciﬁc carrier protein, LPS-binding pro-
tein (LBP), and exposes cells of the innate immune systemAbbreviations: CyDs, cyclodextrins; ELISA, enzyme-linked immuno
sorbent assay; FCS, fetal calf serum; GPI, glycosylphosphatidylinositol;
HP-a-CyD, 2-hydroxypropyl-a-CyD; iNOS, inducible nitric oxide
synthase; LPS, lipopolysaccharide; M-b-CyD, methyl-b-cyclodextrin;
NO, nitric oxide; PEC, peritoneal exudates cells; RT-PCR, reverse
transcriptase-polymerase chain reaction; TLR-4, Toll-like receptor-4;
TNF-a, tumor necrosis factor-a
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doi:10.1016/j.febslet.2005.01.076through a distinct receptor, CD14 [2]. CD14 is a 55-kDa glyco-
sylphosphatidylinositol (GPI)-anchored protein expressed on
monocytes, macrophages and neutrophils [3,4]. The LPS–
CD14 complex then engages a speciﬁc receptor, the Toll-like
receptor 4 (TLR4) and MD-2 complex (TLR4/MD-2 com-
plex), to aﬀord a variety of biological responses, i.e., macro-
phages can be elicited to produce proinﬂammatory
cytokines, such as tumor necrosis factor-a (TNF-a), interleu-
kin-1, interleukin-6, and nitric oxide (NO), as well as to express
cell surface antigens such as MHC class II, CD80 and CD86
[5,6]. These functions are important for establishing innate
immunity against the microorganism. However, excess
amounts of LPS engender a septic shock and life-threatening
organ dysfunction as described above [7].
Cyclodextrins (CyDs) are host molecules, which form inclu-
sion complexes with lipophilic drugs as guests and thus have
been utilized for improving their water solubility and dissolu-
tion rates [8,9]. CyDs have also been reported to interact with
membrane constituents such as cholesterol, phospholipids and
phosphatidylinositols, depending on their cavity sizes, result-
ing in not only the induction of hemolysis of erythrocytes
[10,11] but also the disruption of the structures of lipid rafts
[12–14], lipid microdomains formed by lateral assemblies of
cholesterol and sphingolipids in the cell membrane [15]. Re-
cently, Cuschieri et al. reported that cholesterol depletion with
methyl-b-CyD (M-b-CyD) in THP-1 cells is associated with a
signiﬁcant attenuation of LPS-mediated mitogen-activated
protein kinases activation [16]. We recently reported that 2,6-
di-O-methyl-a-CyD (DM-a-CyD) inhibited NO production
in RAW264.7 cells, a mouse macrophage cell line, stimulated
with LPS from Escherichia coli (serotype O111:B4) [17]. In
the following study, we examined whether DM-a-CyD inhibits
NO and TNF-a production as well as NF-jB activation in var-
ious mouse macrophage cell lines and primary peritoneal exu-
date cells (PECs) stimulated with LPS from E. coli (serotype
O111:B4 and O55:B5) and lipid A. In addition, the involve-
ment of CD14 and TLR4/MD-2 complex in the inhibitory
mechanism of DM-a-CyD was investigated.2. Materials and methods
2.1. Materials
CyDs used in this study are depicted in Table 1. a-CyD, 2-hydroxy-
propyl-a-CyD (HP-a-CyD) and DM-a-CyD were donated from Nihon
Shokuhin Kako (Tokyo, Japan). LPS from E. coli (serotype O111:B4blished by Elsevier B.V. All rights reserved.
Table 1
Chemical structures of CyDs used in this study
n
O
R2O
OOR1
OR3
1
54
3
2
6
Compound Abbreviation n R1 R2 R3 D.S.
a
a-Cyclodextrin a-CyD 6 –H –H –H –
2-Hydroxypropyl-a-cyclodextrin HP-a-CyD 6 –H or –CH2CH(CH3)OH 4.1
2,6-Di-O-methyl-a-cyclodextrin DM-a-CyD 6 –CH3 –H –CH3 12.0
Methyl-b-cyclodextrin M-b-CyD 7 –H or –CH3 12.6
aAverage degree of substitution.
1708 K. Motoyama et al. / FEBS Letters 579 (2005) 1707–1714and O55:B5), ﬂuorescein isothiocyanate (FITC)-conjugated LPS
(O111:B4), lipid A and M-b-CyD were purchased from Sigma (St.
Louis, MO). RPMI-1640 culture medium and fetal calf serum (FCS)
were obtained from Nissui Pharmaceutical (Tokyo, Japan) and JRH
Biosciences (Renexa, KS), respectively. CpG phosphorothioate oligo-
nucleotide (CpG-ODN, 5 0-TCCATGACGTTCCTGACGTT-3 0) was
obtained from Hokkaido System Science (Sapporo, Japan). Deoxyri-
bonuclease I and ribonuclease inhibitor were purchased from Nippon
Gene (Toyama, Japan) and Nacalai Tesque (Kyoto, Japan), respec-
tively. Reverse transcriptase (SuperScript II) and Taq polymerase
(AmpliTaq Gold) were purchased from Invitrogen (Carlsbad, CA)
and Applied Biosystems (Tokyo, Japan), respectively. Thioglycollate
was obtained from Difco Laboratories (Detroit, MI). All other chem-
icals and solvents were of analytical reagent grade.
2.2. Cell culture
RAW264.7, J774.1 andPU5-18 cells (Institute ofDevelopment,Aging
and Cancer, Tohoku University, Sendai, Japan), murine macrophage-
like cell lines and PEC isolated from C3H/HeN mice (4–5 weeks old,
Nihon SLC, Shizuoka, Japan) stimulated with 3% thioglycollate were
incubated with LPS or lipid A at the indicated concentration in RPMI-
1640 culture medium supplemented with 10% heat-inactivated FCS.
2.3. Cell viability and nitrite determination
Cell viability and nitrite production were assayed using a Cell
Counting Kit (WST-1 method) [18,19] from Wako Pure Chemical
Industries (Osaka, Japan) and using Griess reagent [20], respectively,
as reported previously [17].
2.4. Western blot and enzyme-linked immunosorbent assay (ELISA)
Inducible nitric oxide (iNOS) in the RAW264.7 cells and TNF-a in
cell-free supernatant were detected by Western blot and ELISA,
respectively. Brieﬂy, RAW264.7 cells (3 · 106/dish or 1 · 105 cells/well)
were stimulated with 10 lg/ml of LPS for 4 h with or without a-CyDs,
then washed with culture medium and incubated for 4 h in culture
medium. Then, the cells were scraped and lysed. After determining
protein concentrations, samples (20 lg as protein) were separated with
7.5% SDS–PAGE and transferred onto Immobilon P membranes (Ni-
hon Millipore, Tokyo, Japan). The membranes were blocked and incu-
bated with rabbit anti-mouse iNOS antibody (Aﬃnity Bioreagent,
Neshanic Station, NJ) or rabbit anti-goat actin antibody (Santa Cruz
Biotechnology, CA) for 2 h. After washing, the membranes were incu-
bated with peroxidase-conjugated goat anti-rabbit IgG antibody (Cap-
pel, Durham, NC) or peroxidase-conjugated anti-rabbit IgG antibody
(Amersham Biosciences, Tokyo, Japan). Speciﬁc bands were detected
using an ECLWestern blot analysis kit (Amersham Bioscience, Tokyo,
Japan). The level of TNF-a in cell-free supernatants was routinely as-
sayed by a sandwich ELISA using pairs of puriﬁed capture and detec-
tion monoclonal antibodies recognizing murine TNF-a (Pharmingen,
San Diego, CA), according to the manufacturers protocols.
2.5. Reverse transcriptase-polymerase chain reaction (RT-PCR)
analysis
The levels of iNOS mRNA and TNF-a mRNA in cells were assayed
by semiquantitative RT-PCR method as reported previously [17]. To-
tal RNA was isolated from RAW264.7 cells (3 · 106 cells/dish) follow-ing the manufacturers instructions. cDNA was synthesized using a
reverse primer and SuperScript II. The primer sequences were as fol-
lows: mouse b-actin: forward, 5 0-TTGGCATAGAGGTCTTTACG-
GA-3 0; reverse, 5 0-GCACCACACCTTCTACAATGAG-3 0; mouse
TNF-a forward, CTCCTGGTATGAGATAGCAAA-3 0 and reverse,
5 0-CAAAGGGATGAGAAGTTCCCAA-3 0; iNOS forward, 5 0-ACA-
GGGAAGTCTGAAGCACTAG-3 0, reverse, 5 0-CATGCAAGGAA-
GGGAACTCTTC-3 0.2.6. NF-jB activation
RAW264.7 cells (2 · 106 cells/dish) were stimulated with LPS
(1000 ng/ml) with or without a-CyDs for 15 min. After LPS treatment,
the cells were ﬁxed in methanol, incubated with mouse anti-NF-jB p65
mAb for 1 h. Primary antibody was detected with FITC-conjugated
goat anti-mouse IgG2a. Samples were viewed and photographed by
using a confocal ﬂuorescence microscopic system (Olympus FV300-
BX, Tokyo) with an argon ion laser (excitaion wavelength, 488 nm).2.7. Flow cytometry
RAW264.7 cells (2 · 106 cells/dish) were incubated with or without
10 mM a-CyDs at 4 C for 30 min. The cells were washed with HBSS
and incubated with FITC-conjugated anti-CD14 or anti-TLR4/MD-2
complex antibody (MTS510) at 4 C for 30 min. In the latter case, the
cells were washed with PBS twice and incubated with FITC-conjugate
anti-IgG2a at 4 C for 30 min. The stained cells were resuspended in
HBSS and were quantiﬁed using a FACSCalibur ﬂow cytometer with
CellQuest software (Becton Dickinson, Mountain View, CA).
2.8. Release of CD14 from lipid rafts
RAW264.7 cells (3 · 106 cells/dish) were incubated with a-CyDs at
the designated concentration at 37 C for 1 h. The CD14 released from
the cells into the cell supernatant was concentrated with 10% trichloro-
acetic acid and was then assayed by Western blot as described above.
Rat anti-mouse CD14 monoclonal Ab (Pharmingen, San Diego, CA)
and HRP-goat anti-rat IgG Ab (Amersham Bioscience, Tokyo, Japan)
were used for this assay. In addition, low-density lipid raft-enriched
domains were isolated by a carbonate-based fractionation method as
described previously [21].
2.9. Released cholesterol and phospholipids determination
RAW264.7 cells (2 · 106 cells/dish) were incubated for 10 h in growth
medium supplemented with 10%FCS containing [3H]cholesterol (5 lCi/
ml of serum). Prior to experiments, the cells were incubated in HBSS
containing various concentrations of a-CyDs and M-b-CyD. The total
amount of [3H]cholesterol in the cells was detected by the same method
after lysed in 1 NNaOH. The concentrations of [3H]cholesterol inHBSS
were determined with an Aloka LSC-3500 liquid scintillation counter.
The concentrations of phospholipids released from the cells in the buﬀer
were determined using a Phospholipids Kit Wako (Wako Pure Chem-
ical Industries, Osaka, Japan).
2.10. Statistical analysis
Data are given as means ± S.E.M. Statistical signiﬁcance of means
for the studies was determined by analysis of variance followed by
Scheﬀes test. P-values for signiﬁcance were set at 0.05.
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3.1. Cytotoxicity of CyDs
We examined the eﬀects of a-CyDs on the viability of mac-
rophages using the WST-1 method. In the range of low con-
centrations, none of the a-CyDs showed cytotoxicity for
RAW264.7 cells (Fig. 1A), but in the range of high concentra-
tions the viability was decreased by adding a-CyDs and LD50
values lowered in the order of HP-a-CyD > a-CyD > DM-a-
CyD (Fig. 1B). In addition, similar cytotoxic eﬀects of a-CyDs
were observed on other mouse macrophages such as PU5-18,: α-CyD
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Fig. 1. Cytotoxicty of a-CyDs in RAW264.7 cells. RAW264.7 cells (1 · 10
supplemented with 10% FCS containing CyDs at the designated concentra
concentrations of a-CyDs were up to 10 mM (A) and 100 mM (B), respectiv
Fig. 2. DM-a-CyD inhibits NO production in RAW264.7 cells and PEC st
CpG-ODN. Macrophages (1 · 105) were incubated for 1 h with 150 ll of RPM
lipid A or CpG-ODN with or without a-CyDs. After washes with PBS to remo
level in the culture supernatant was assayed by the Griess method. (A, B) The
was 10 mM, respectively. (C) The concentrations of LPS were 0 ng/ml (closed
triangle) and 1000 ng/ml (closed square), respectively. Each value represent
alone. (D) The concentrations of CpG-ODN were 5 and 10 lg/ml and
means ± S.E.M. of ﬁve experiments.J774.1 and PEC (data not shown). These results indicate that
of a-CyDs used here DM-a-CyD interacts to the greatest ex-
tent with these macrophages.
3.2. DM-a-CyD suppressed NO and TNF-a production in
macrophages stimulated with LPS
To reveal whether DM-a-CyD inhibits NO and TNF-a pro-
duction in various mouse macrophages stimulated with LPS,
we assayed nitrite and TNF-a levels in the cell supernatant
24 h after stimulation with LPS by the Griess method [20]
and ELISA, respectively. DM-a-CyD had a superior120
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5) were incubated for 1 h with 150 ll of RPMI-1640 culture medium
tions. The cell viability was assayed using a Cell Counting Kit. The
ely. Each point represents means ± S.E.M. of three experiments.
imulated with LPS (O111:B4), LPS (O55:B5) or lipid A, but not with
I-1640 culture medium supplemented with 10% FCS containing LPS,
ve their ligands and CyDs, the cells were incubated for 24 h. The nitrite
concentration of LPS and lipid A was 1000 ng/ml, and that of a-CyDs
circle), 1 ng/ml (open circle), 10 ng/ml (closed triangle), 100 ng/ml (open
s means ± S.E.M. of three experiments. \P < 0.05, compared to LPS
that of a-CyDs was 10 mM, respectively. Each value represents
1710 K. Motoyama et al. / FEBS Letters 579 (2005) 1707–1714inhibitory eﬀect on NO production in RAW264.7 cells as well
as PEC stimulated with LPS (serotype O111:B4), LPS (serotype
O55:B5) or lipid A, to a-CyD and HP-a-CyD (Fig. 2A and B).
Almost the same inhibitory eﬀect of DM-a-CyD was elicited in
PU5-18 and J774.1 cells (data not shown). In addition, the
inhibitory eﬀect of DM-a-CyD was concentration-dependent
when stimulated with LPS (serotype O111:B4) at the various
concentrations in RAW264.7 cells (Fig. 2C). These results sug-
gest that DM-a-CyD provides an inhibitory eﬀect on NO and
TNF-a production not only in mouse macrophage-like cell
lines but also in primary macrophages with stimulated with
two types of LPSs and lipid A. Furthermore, a-CyDs did
not allow to change NO production in RAW264.7 cells stimu-
lated with CpG-ODN, a TLR9 ligand (Fig. 2D). It is possible
that the inhibitory eﬀects of DM-a-CyD are due to the interac-
tion with the lipid A moiety of LPS and/or cell surface, because
a-CyDs fail to enter cells.
Next, we examined whether DM-a-CyD suppresses iNOS
and TNF-a expression. In subsequent experiments, we used
LPS (serotype O111:B4) as a stimulant. As shown in Fig. 3,
an iNOS band at 130 kDa was observed in extracts of cells
stimulated with LPS, whereas the treatment with 5 mM DM-
a-CyD attenuated iNOS expression. However, in the case of
other a-CyDs treatments, the band densities were almost the
same as that of the control (Fig. 3A). In addition, the three
a-CyDs used here did not alter the control actin band densities
(Fig. 3A). Moreover, the inhibitory eﬀects of DM-a-CyD on
iNOS expression, not actin expression, were concentration-
dependent (Fig. 3B). Fig. 3C shows the iNOS mRNA levels
determined by RT-PCR of total RNA in RAW264.7 cells.
DM-a-CyD caused a substantial reduction in the density ofFig. 3. DM-a-CyD inhibits expression of iNOS (A, B) and iNOS mRNA (C
were stimulated with 10 lg/ml of LPS for 4 h with or without a-CyDs, and t
and actin in RAW264.7 cells were detected by Western blot (A, B) and iNOSm
D), respectively. (A, C) The concentrations of LPS and CyDs were 10 lg/ml a
1, 3 and 5 mM. These ﬁgures show representative data for three experimentthe 1033 bp band derived from iNOS mRNA but not in that
of the 630-bp band of control b-actin mRNA (Fig. 3C). Like-
wise, the band densities after treatment with DM-a-CyD low-
ered in a concentration-dependent manner (Fig. 3D).
Therefore, these results suggest that DM-a-CyD suppresses
iNOS gene expression in RAW264.7 cells stimulated with
LPS. Similarly, DM-a-CyD inhibited TNF-a production in
RAW264.7 cells, but other a-CyDs did not (Fig. 4A). In addi-
tion, the TNF-a mRNA levels were lowered by the addition of
DM-a-CyD (Fig. 4B), whereas the suppressive eﬀect was con-
centration-dependent (Fig. 4C). Thus, DM-a-CyD is likely to
attenuate iNOS and TNF-a expression at a pre-transcriptional
level.
3.3. DM-a-CyD blocked NF-jB translocation into nucleus
LPS signaling mediated by myeloid diﬀerentiation factor 88
requires NF-jB activation and involves the production of
inﬂammatory cytokines such as TNF-a, interleukin-1, interleu-
kin-6 and NO. Then, we investigated whether DM-a-CyD pre-
vents NF-jB activation when stimulated with LPS. In the
absence of LPS, NF-jB was observed in cytoplasm (Fig.
5A). Upon LPS stimulation, NF-jB obviously translocated
to nucleus (Fig. 5B). The addition of DM-a-CyD signiﬁcantly
inhibited NF-jB translocation (Fig. 5C). Therefore, the inhib-
itory eﬀects of DM-a-CyD on NO and TNF-a production may
result from the inhibitory eﬀects on NF-jB activation.
3.4. DM-a-CyD released CD14 from lipid rafts
To gain insight into the inhibitory mechanism of DM-a-
CyD for the LPS signaling, we examined the CD14 and
TLR4/MD-2 complex expressions on the surface of, D) in RAW264.7 cells stimulated with LPS. RAW264.7 cells (3 · 106)
hen washed with culture medium, and further incubated for 4 h. iNOS
RNA and b-actinmRNA in the cells were determined by RT-PCR (C,
nd 5 mM, respectively. (B, D) The concentrations of DM-a-CyD were
s.
Fig. 4. DM-a-CyD inhibits expression of TNF-a (A) and TNF-a mRNA (B, C) in RAW264.7 cells stimulated with LPS at various concentrations.
(A) RAW264.7 cells (1 · 105) were stimulated with LPS at the concentration of 0 (open bar), 10 (brick bar) and 1000 (solid bar) ng/ml, respectively,
for 1 h with or without of 10 mM a-CyDs, and then washed with culture medium, and incubated for 15 h. The TNF-a released in the culture
supernatant was detected by ELISA. Each value represents means ± S.E.M. of three experiments. \P < 0.05, compared to LPS alone. (B, C)
RAW264.7 cells (3 · 106) were stimulated with LPS at 10 ng/ml for 1 h with or without a-CyDs. After a wash, total RNA was isolated from the cells
and the TNF-a mRNA in RAW264.7 cells was detected by RT-PCR (B, C). These ﬁgures show representative data for three experiments.
Fig. 5. DM-a-CyD inhibits the translocation of NF-jB to nucleus in RAW264.7 cells. RAW264.7 cells (2 · 106 cells) were stimulated with LPS
(1000 ng/ml) for 15 min before ﬁxation by methanol for 5 min. The mouse anti-NF-jB p65 was treated overnight at 4 C. The goat anti-mouse IgG-
FITC was added to the cells and incubated for 1 h at 37 C. Slides were analyzed under a confocal ﬂuorescence microscopic system. These ﬁgures
show representative data for three experiments.
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with DM-a-CyD shifted the curve corresponding to CD14 to
the left-hand side, while treatment with the other a-CyDs did
not (Fig. 6A). Additionally, the shifts in the DM-a-CyD sys-
tem were dose-dependent (Fig. 6B). While none of the a-CyDs
shifted the curve corresponding to TLR4/MD-2 complex on
the RAW264.7 cells (Fig. 6C). Thus, the suppressive eﬀects
of DM-a-CyD on LPS signaling may result from impairment
of CD14 expression on the plasma membranes.
It was recently reported that CD14 and TLR4/MD-2 com-
plex reside in lipid rafts [22–24]. We reported that DM-b-
CyD released P-glycoprotein and MRP2 from caveolae,
ﬂask-shaped lipid microdomains, of vinblastine-resistant
Caco-2 cells [25]. Therefore, we examined whether a-CyDs re-lease CD14 and TLR4/MD-2 complex from the lipid rafts.
Consistent with the ﬁnding reported by Pfeiﬀer et al. [23],
CD14 resided in lipid raft fractions (Fig. 7A) irrespective of
LPS, whereas the treatment of RAW264.7 cells with DM-a-
CyD markedly lowered the CD14 band density (Fig. 7A). To
determine the eﬀect of DM-a-CyD on CD14 expression in
and outside of lipid raft fractions, samples were loaded in each
lane after adjusting the protein content. Determining the band
density using the NIH image, the treatment with DM-a-CyD
decreased CD14 levels in rafts to 27.2% relative to the control
(Fig. 7B). These results suggest that DM-a-CyD attenuates the
CD14 level in lipid rafts. Indeed, the band corresponding to
CD14 was clearly observed in culture medium after treatment
with DM-a-CyD compared with that with a-CyD and
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Fig. 6. DM-a-CyD lowers the expression of CD14, but not TLR4/
MD-2 complex, on the surface of RAW264.7 cells. RAW264.7 cells
(2 · 106) were incubated with or without 10 mM a-CyDs at 4 C for
30 min. The cells were washed with HBSS and incubated with FITC-
conjugated anti-CD14 (A, B) or anti-TLR4/MD-2 complex antibody
(C) at 4 C for 30 min. In the latter case, the cells were washed with
PBS twice and incubated with FITC-conjugated anti-IgG2a at 4 C for
30 min (C). After a wash, the stained cells were resuspended in HBSS
and were quantiﬁed using a ﬂow cytometer. These ﬁgures show
representative data for three experiments.
1712 K. Motoyama et al. / FEBS Letters 579 (2005) 1707–1714HP-a-CyD (Fig. 7C). In addition, the eﬀect of DM-a-CyD to
release CD14 in the medium was in a concentration-dependent
manner (Fig. 7D). However, DM-a-CyD neither released
TLR4/MD-2 complex from the cells nor translocated outside
of lipid rafts (data not shown). Taken together, it is evident
that DM-a-CyD uniquely extracts CD14, but not TLR4/
MD-2 complex, from lipid rafts into culture medium.
3.5. DM-a-CyD released phospholipids rather than cholesterol
from cells
CyDs are known to extract membrane lipids such as choles-
terol and phospholipids from liposomes and cellular mem-
branes [26]. To address the question of how DM-a-CyD
releases CD14 from lipid rafts of RAW264.7 cells, we investi-
gated the eﬀects of a-CyDs and M-b-CyD, a novel cholesterol
depletion agent, on the release of membrane components. Asexpected, M-b-CyD released cholesterol, but other a-CyDs
did not (Fig. 8A). To the contrary, DM-a-CyD markedly re-
leased phospholipids from the cells, compared with other a-
CyDs (Fig. 8B). Taken together, these results suggest that
membrane perturbation elicited by DM-a-CyD through
extraction of phospholipids leads to CD14 release from lipid
rafts.4. Discussion
This is the ﬁrst report showing that of three a-CyDs, DM-a-
CyD inhibits LPS signaling in murine macrophage cell lines
and primary PEC stimulated with two types of LPS and lipid
A, likely due to the release of CD14 from the lipid rafts of
these cells to supernatants.
HP-a-CyD and DM-a-CyD have higher solubility in water
than a-CyD, and they are surface active [27]. Besides, DM-a-
CyD has hemolytic activity higher than a-CyD and HP-a-
CyD, suggesting the superior interaction with erythrocytes to
HP-a-CyD and a-CyD. Thus, we hypothesized that of these
a-CyDs, DM-a-CyD markedly suppresses LPS signaling
through the interaction with LPS and/or cell membranes. As
predicted, DM-a-CyD had the most potent inhibitory eﬀects
on the LPS signaling in macrophages without cytotoxicity,
compared with other a-CyDs used here (Figs. 1–5).
The ability of DM-a-CyD to release CD14 from lipid rafts
may result in LPS signaling in macrophages. In our previous
study, DM-a-CyD indeed ameliorated cellular binding of
LPS to RAW264.7 cell [16], and CyDs are generally known
to be impermeable through lipid bilayers owing to their hydro-
philic properties with high molecular weight [27]. Additionally,
CD14 was extracted from cell membranes to a supernatant in
response to DM-a-CyD (Figs. 6 and 7). Besides, CD14 was
found to localize in lipid rafts as mentioned by Miyake [28]
and was released from the microdomains to supernatant by
treatment with DM-a-CyD in a concentration-dependent man-
ner (Fig. 7). Taken together, it is likely that CD14 released by
DM-a-CyD from lipid rafts is involved in the impairment of
LPS signaling.
DM-a-CyD is likely to release CD14 through indirect inter-
action with proteins because CyDs are known to interact with
proteins to a lesser extent and prefers the inclusion complexa-
tion with phospholipids to cholesterol [27]. Our results also
showed that DM-a-CyD released CD14 from lipid rafts (Fig.
7), irrespective of the very slight interaction with cholesterol.
An addition of free phosphatidylcholine, not cholesterol, to
DM-a-CyD-containing buﬀer completely inhibited the release
of CD14 into the culture medium (data not shown). Interest-
ingly, M-b-CyD neither released CD14 nor blocked NF-jB
activation under the present experimental conditions (data
not shown). These results indicate that the eﬀects of DM-a-
CyD on LPS signaling in macrophages are totally diﬀerent
from that of M-b-CyD. Furthermore, CD14 release induced
by DM-a-CyD seems to be exerted by the secondary eﬀect of
lipid extraction from the membranes.
However, DM-a-CyD and other a-CyDs failed to release
TLR4/MD-2 complex from the cell membranes (Fig. 6), par-
tially consistent with the results reported by Cuschieri et al.
[16,29]. This fact might be related to the diﬀerence in mem-
brane topology between CD14 and TLR4/MD-2 because
CD14 and TLR4/MD-2 complex are a GPI-anchored protein
Fig. 7. DM-a-CyD releases CD14 from lipid rafts of RAW264.7 cells into culture medium in a concentration-dependent manner. RAW264.7 cells
(3 · 106) were treated with 1000 ng/ml of LPS or 10 mM a-CyDs for 1 h at 37 C. (A) After isolation of lipid rafts, the CD14 levels in all of fractions
were assayed by immunoblot. (B) DM-a-CyD lowers the CD14 level in lipid rafts. CD14 levels in lipid rafts were assayed by immunoblot after
adjusting the total protein content (5 and 10 lg proteins/lane in lipid rafts and non-rafts, respectively). (C) DM-a-CyD extracts CD14 from lipid rafts
of the cells to culture medium. CD14 released to culture medium was detected by immunoblot. (D) The ability of DM-a-CyD to release CD14 was
concentration-dependent. These ﬁgures show representative data for three experiments.
Fig. 8. DM-a-CyD releases phospholipids, but not [3H]cholesterol
from RAW264.7 cells. RAW264.7 cells (3 · 106) were labeled with
[3H]cholesterol and then treated with 10 mM CyDs for 1 h at 37 C.
(A) The radioactivity of [3H]cholesterol in HBSS was assayed using a
liquid scintillation counter. Each value represents means ± S.E.M. of
3–4 experiments. \P < 0.05, compared to LPS alone. (B) The concen-
trations of phospholipids released in the supernatant were measured
using a Phospholipids Kit Wako. Each value represents means ±
S.E.M. of six experiments. \P < 0.05 versus control.
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underway to investigate whether DM-a-CyD speciﬁcally re-
leases GPI-anchored proteins from lipid rafts.
Recently, there have been some interesting reports that (1)
LPS is predominantly taken up via CD14-mediated pathways,
not TLR4 pathway [30], (2) LPS is rapidly delivered from the
plasma membrane to an intracellular site [31], (3) LPS is inter-
nalized and then rapidly encounters intracellular TLR4, and
downstream signaling is triggered [32]. These lines of evidence
as well as our present results make it tempting to speculate that
DM-a-CyD ﬁrst extracts membrane lipids, and then releasesCD14 from lipid rafts, and then LPS endocytosis and/or LPS
transfer to TLR4 disappears, resulting in blocking TLR4 sig-
naling pathway towards NF-jB activation. Another possibility
may be proposed that DM-a-CyD may disturb a cluster of
receptors comprising TLR4, CD11b/CD18, CD55, CD81,
hsp70, hsp90, GDF5 and CXCR4 which are crucial for
TLR4 signal following LPS stimulation [33]. Thus, elaborate
studies are further required to decipher the detailed mechanism
by which DM-a-CyD aﬀects LPS signaling from lipid rafts.
DM-a-CyD is likely to have diﬀerent properties from vari-
ous LPS antagonists, e.g., polymyxin B, Eritoran (E5564),
HA-1A, E5 and surfactant protein A [34–37], since the inhib-
itory eﬀect of DM-a-CyD is likely to be associated with
CD14. Our preliminary spectrophotometric study demon-
strates the direct interaction of LPS with DM-a-CyD was ob-
served only very slightly (data not shown). Thus, it is possible
that DM-a-CyD is a highly potent and unique endotoxin
antagonist.
CD14 is well known to be associated with various diseases,
e.g., asthma bronchial, systemic lupus erythematosus, atopic
dermatitis, chronic hepatitis B and C infection, alcoholic liver
cirrhosis and rheumatoid arthritis [38]. Recently, Fassebender
et al. have suggested that CD14 links innate immunity with
Alzheimers disease (AD) [39]: CD14 interacts with amyloid
peptide, and then promotes neuroinﬂammation in AD.
Therefore, our results lead us to expect the possibility that
DM-a-CyD may be useful for an inhibitor of CD14 to reduce
the central and peripheral inﬂammation.
In conclusion, the present study suggests that DM-a-CyD
impaired LPS signaling in murine macrophages stimulated
with LPS and lipid A. The inhibitory eﬀect of DM-a-CyD
could be attributed to the release of CD14 from lipid rafts
caused by eﬄux of phospholipids, but not by cholesterol.
These results suggest that DM-a-CyD may be useful as a
1714 K. Motoyama et al. / FEBS Letters 579 (2005) 1707–1714potent antagonist for excess activation of macrophages stimu-
lated with LPS.
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